Published in Eur J Haematol on March 30, 2011
Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins. Front Oncol (2012) 0.92
Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies. PLoS One (2013) 0.85
Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells. Front Oncol (2012) 0.84
Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines. J Immunol Res (2015) 0.77
Increased generation of HIV-1 gp120-reactive CD8+ T cells by a DNA vaccine construct encoding the chemokine CCL3. PLoS One (2014) 0.77
Targeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in mice. J Transl Med (2014) 0.75
Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science (2002) 4.45
Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity. EMBO J (2006) 3.07
Primary antitumor immune response mediated by CD4+ T cells. Immunity (2005) 2.72
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood (2011) 1.71
Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun (2011) 1.49
Cutting edge: expression of XCR1 defines mouse lymphoid-tissue resident and migratory dendritic cells of the CD8α+ type. J Immunol (2011) 1.39
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer (2008) 1.27
Cutting edge: link between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4+ T cells and could be an efficient vaccine target. J Immunol (2003) 1.13
A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease. PLoS One (2012) 1.07
CXCR1/2 inhibition enhances pancreatic islet survival after transplantation. J Clin Invest (2012) 1.05
Systemic autoimmune disease caused by autoreactive B cells that receive chronic help from Ig V region-specific T cells. J Immunol (2005) 1.05
Lymphomas can develop from B cells chronically helped by idiotype-specific T cells. J Exp Med (2007) 1.05
A site-specific plectin mutation causes dominant epidermolysis bullosa simplex Ogna: two identical de novo mutations. J Invest Dermatol (2002) 1.03
Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells. Cancer Res (2009) 1.03
Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood (2004) 1.03
Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer. J Cell Physiol (2010) 1.02
Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells. Cell Rep (2013) 1.02
Delivery of antigen to CD40 induces protective immune responses against tumors. J Immunol (2007) 1.01
The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma. Br J Haematol (2012) 1.00
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood (2013) 0.98
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol (2014) 0.96
Non-invasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma. PLoS One (2012) 0.96
Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences. Blood (2007) 0.94
A mouse C kappa-specific T cell clone indicates that DC-SIGN is an efficient target for antibody-mediated delivery of T cell epitopes for MHC class II presentation. Int Immunol (2002) 0.93
Monoclonal antibodies produced by muscle after plasmid injection and electroporation. Mol Ther (2004) 0.93
Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies. Blood (2003) 0.93
MHC-restricted Ig V region-driven T-B lymphocyte collaboration: B cell receptor ligation facilitates switch to IgG production. J Immunol (2004) 0.93
Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8+ T-cell responses against influenza virus. Eur J Immunol (2014) 0.93
DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Mol Ther (2006) 0.91
TLR3-responsive, XCR1+, CD141(BDCA-3)+/CD8α+-equivalent dendritic cells uncovered in healthy and simian immunodeficiency virus-infected rhesus macaques. J Immunol (2014) 0.91
Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis. J Leukoc Biol (2004) 0.90
Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model. BMC Cancer (2011) 0.88
Safety and pharmacokinetics of escalating doses of human recombinant nerve growth factor eye drops in a double-masked, randomized clinical trial. BioDrugs (2014) 0.87
Indirect CD4+ T-cell-mediated elimination of MHC II(NEG) tumor cells is spatially restricted and fails to prevent escape of antigen-negative cells. Eur J Immunol (2014) 0.87
The cellular mechanism by which complementary Id+ and anti-Id antibodies communicate: T cells integrated into idiotypic regulation. Immunol Cell Biol (2010) 0.86
Expanding the versatility of phage display II: improved affinity selection of folded domains on protein VII and IX of the filamentous phage. PLoS One (2011) 0.86
Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma. Immunol Lett (2013) 0.86
DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza. J Immunol (2013) 0.85
A model for cancer-suppressive inflammation. Oncoimmunology (2012) 0.85
Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells. Front Oncol (2012) 0.84
Splice site and deletion mutations in keratin (KRT1 and KRT10) genes: unusual phenotypic alterations in Scandinavian patients with epidermolytic hyperkeratosis. J Invest Dermatol (2003) 0.84
Tracking early autoimmune disease by bioluminescent imaging of NF-kappaB activation reveals pathology in multiple organ systems. Am J Pathol (2009) 0.84
Molecular profiling of tumor-specific TH1 cells activated in vivo. Oncoimmunology (2013) 0.84
Chemotherapy-related cardiotoxicity: new diagnostic and preventive strategies. Ital Heart J (2003) 0.83
Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice. Blood (2012) 0.83
BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations? Med Oncol (2011) 0.83
Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma. J Clin Invest (2015) 0.82
Efficient delivery of T cell epitopes to APC by use of MHC class II-specific Troybodies. J Immunol (2002) 0.82
Human chemokine MIP1α increases efficiency of targeted DNA fusion vaccines. Vaccine (2010) 0.82
The specificity of targeted vaccines for APC surface molecules influences the immune response phenotype. PLoS One (2013) 0.82
CD4+ T cells kill Id+ B-lymphoma cells: FasLigand-Fas interaction is dominant in vitro but is redundant in vivo. Cancer Immunol Immunother (2004) 0.81
Chaperone-assisted thermostability engineering of a soluble T cell receptor using phage display. Sci Rep (2013) 0.81
Human receptors of innate immunity (CD14, TLR2) are promising targets for novel recombinant immunoglobulin-based vaccine candidates. Vaccine (2007) 0.81
Expression of SH2D2A in T-cells is regulated both at the transcriptional and translational level. Mol Immunol (2007) 0.79
Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research. Haematologica (2006) 0.79
Protein C deficiency caused by homozygosity for a novel PROC D180G mutation--in vitro expression and structural analysis of the mutation. Thromb Haemost (2002) 0.79
A VH4-34+ myeloma protein with weak autoreactivity. Haematologica (2007) 0.78
APC mutation spectrum of Norwegian familial adenomatous polyposis families: high ratio of novel mutations. J Cancer Res Clin Oncol (2009) 0.78
Armed antibodies for cancer treatment: a promising tool in a changing era. Cancer Immunol Immunother (2014) 0.78
Cerebrospinal fluid T cell clones from patients with multiple sclerosis: recognition of idiotopes on monoclonal IgG secreted by autologous cerebrospinal fluid B cells. Eur J Immunol (2005) 0.78
Heterodimeric barnase-barstar vaccine molecules: influence of one versus two targeting units specific for antigen presenting cells. PLoS One (2012) 0.78
Efficient vaccine against pandemic influenza: combining DNA vaccination and targeted delivery to MHC class II molecules. Expert Rev Vaccines (2015) 0.78
Periplasmic expression of soluble single chain T cell receptors is rescued by the chaperone FkpA. BMC Biotechnol (2010) 0.78
Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models. Cancer Immunol Immunother (2004) 0.78
Expanding the versatility of phage display I: efficient display of peptide-tags on protein VII of the filamentous phage. PLoS One (2011) 0.77
CD40/APC-specific antibodies with three T-cell epitopes loaded in the constant domains induce CD4+ T-cell responses. Protein Eng Des Sel (2012) 0.77
DeltaPhage--a novel helper phage for high-valence pIX phagemid display. Nucleic Acids Res (2012) 0.77
Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies. Cancer Immunol Immunother (2014) 0.77
Processing of an antigenic sequence from IgG constant domains for presentation by MHC class II. J Immunol (2008) 0.77
Antibody-mediated delivery of antigen to chemokine receptors on antigen-presenting cells results in enhanced CD4+ T cell responses. Eur J Immunol (2003) 0.76
Germ cell tumors overexpress the candidate therapeutic target cyclin B1 independently of p53 function. Int J Biol Markers (2015) 0.76
SH2D2A modulates T cell mediated protection to a B cell derived tumor in transgenic mice. PLoS One (2012) 0.76
Stabilizing mutations increase secretion of functional soluble TCR-Ig fusion proteins. BMC Biotechnol (2010) 0.76
Recombinant antibodies for delivery of antigen: a single loop between beta-strands in the constant region can accommodate long, complex and tandem T cell epitopes. Int Immunol (2008) 0.76
The idiotype connection: linking infection and multiple sclerosis. Trends Immunol (2009) 0.76
Induction of central T cell tolerance: recombinant antibodies deliver peptides for deletion of antigen-specific (CD4+)8+ thymocytes. Eur J Immunol (2005) 0.76
Targeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in mice. J Transl Med (2014) 0.75
[Allogeneic stem cell transplantation in acute myelogenous leukemia]. Tidsskr Nor Laegeforen (2008) 0.75
Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning. Ther Drug Monit (2015) 0.75
Cloning of B cell lymphoma-associated antigens using modified phage-displayed expression cDNA library and immunized patient sera. J Immunol Methods (2006) 0.75
Fibroblast heterogeneity in collagenolytic response to colchicine. Biochem Pharmacol (2005) 0.75
[Treatment of T-cell prolymphocytic leukemia with monoclonal anti- CD52 antibody (alemtuzumab]. Tidsskr Nor Laegeforen (2004) 0.75
Human CD14 is an efficient target for recombinant immunoglobulin vaccine constructs that deliver T cell epitopes. J Leukoc Biol (2004) 0.75
Gene symbol: APC. Hum Genet (2007) 0.75
Naive idiotope-specific B and T cells collaborate efficiently in the absence of dendritic cells. J Immunol (2014) 0.75
B-cell tolerance to the B-cell receptor variable regions. Eur J Immunol (2013) 0.75
[DNA--the future in vaccine technology?]. Tidsskr Nor Laegeforen (2006) 0.75
[Allogeneic stem cell transplantation in adults with acute lymphoblastic leukaemia]. Tidsskr Nor Laegeforen (2008) 0.75
[Epidermolysis bullosa simplex Dowling-Meara]. Ugeskr Laeger (2006) 0.75
Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group. Clin Lymphoma Myeloma Leuk (2010) 0.75